Movement Alert｜WuXi AppTec Rises 3.34% in Regular Trading, Large-Scale Buyback Combined with Innovative Drug Sector Recovery

Market Focus06-22

On June 22, WuXi AppTec rose 3.34% in regular trading, trading at HK$133.0/share, with turnover of HK$476 million.

On the news front, the company recently completed the repurchase of approximately 20.15 million H-shares under its H-Share Award Trust Scheme, totaling HK$2.5 billion and representing roughly 0.68% of total share capital. Additionally, the company disclosed a nearly RMB 1 billion A-share buyback plan on June 9 and has been repurchasing approximately RMB 100 million worth of A-shares daily since June 12, with shares designated for employee stock ownership plans.

Meanwhile, the broader innovative drug sector has been gaining momentum, with multiple pharmaceutical companies launching buyback and stake-increase programs in June, gradually restoring market confidence in the industry. Sector peers including WuXi Biologics and GenScript Biotech also recorded gains during recent sessions, reflecting a broader recovery in the contract research and manufacturing organization space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198280296?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 14:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198280296","market":"hk","top_or_hot":-1,"title":"Movement Alert｜WuXi AppTec Rises 3.34% in Regular Trading, Large-Scale Buyback Combined with Innovative Drug Sector Recovery","media":"Market Focus","content":"<p><p>On June 22, WuXi AppTec rose 3.34% in regular trading, trading at HK$133.0/share, with turnover of HK$476 million.</p><p>On the news front, the company recently completed the repurchase of approximately 20.15 million H-shares under its H-Share Award Trust Scheme, totaling HK$2.5 billion and representing roughly 0.68% of total share capital. Additionally, the company disclosed a nearly RMB 1 billion A-share buyback plan on June 9 and has been repurchasing approximately RMB 100 million worth of A-shares daily since June 12, with shares designated for employee stock ownership plans.</p><p>Meanwhile, the broader innovative drug sector has been gaining momentum, with multiple pharmaceutical companies launching buyback and stake-increase programs in June, gradually restoring market confidence in the industry. Sector peers including WuXi Biologics and GenScript Biotech also recorded gains during recent sessions, reflecting a broader recovery in the contract research and manufacturing organization space.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WuXi AppTec Rises 3.34% in Regular Trading, Large-Scale Buyback Combined with Innovative Drug Sector Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WuXi AppTec Rises 3.34% in Regular Trading, Large-Scale Buyback Combined with Innovative Drug Sector Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-22 14:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 22, WuXi AppTec rose 3.34% in regular trading, trading at HK$133.0/share, with turnover of HK$476 million.</p><p>On the news front, the company recently completed the repurchase of approximately 20.15 million H-shares under its H-Share Award Trust Scheme, totaling HK$2.5 billion and representing roughly 0.68% of total share capital. Additionally, the company disclosed a nearly RMB 1 billion A-share buyback plan on June 9 and has been repurchasing approximately RMB 100 million worth of A-shares daily since June 12, with shares designated for employee stock ownership plans.</p><p>Meanwhile, the broader innovative drug sector has been gaining momentum, with multiple pharmaceutical companies launching buyback and stake-increase programs in June, gradually restoring market confidence in the industry. Sector peers including WuXi Biologics and GenScript Biotech also recorded gains during recent sessions, reflecting a broader recovery in the contract research and manufacturing organization space.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02359","symbol_name":"药明康德","start_time":0,"source_url":"","article_id":"1198280296","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198280296","pubTimestamp":1782109839,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 22, WuXi AppTec rose 3.34% in regular trading, trading at HK$133.0/share, with turnover of HK$476 million.On the news front, the company recently completed the repurchase of approximately...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02359":"药明康德"},"translate_title":"运动快讯|药明康德常规交易涨3.34%大规模回购叠加创新药板块回暖","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02359":1},"content_text":"On June 22, WuXi AppTec rose 3.34% in regular trading, trading at HK$133.0/share, with turnover of HK$476 million.On the news front, the company recently completed the repurchase of approximately 20.15 million H-shares under its H-Share Award Trust Scheme, totaling HK$2.5 billion and representing roughly 0.68% of total share capital. Additionally, the company disclosed a nearly RMB 1 billion A-share buyback plan on June 9 and has been repurchasing approximately RMB 100 million worth of A-shares daily since June 12, with shares designated for employee stock ownership plans.Meanwhile, the broader innovative drug sector has been gaining momentum, with multiple pharmaceutical companies launching buyback and stake-increase programs in June, gradually restoring market confidence in the industry. Sector peers including WuXi Biologics and GenScript Biotech also recorded gains during recent sessions, reflecting a broader recovery in the contract research and manufacturing organization space.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198280296","isCrawlerRequest":true}